Claims
- 1. An isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide encoding a polypeptide having the deduced amino acid sequence of SEQ ID No. 2 or a fragment, analog or derivative of said polypeptide; and (b) a polynucleotide encoding a polypeptide having the amino acid sequence encoded by the cDNA contained in ATCC Deposit No. 75902 or a fragment, analog or derivative of said polypeptide.
- 2. The polynucleotide of claim 1 wherein the polynucleotide is DNA.
- 3. The polynucleotide of claim 1 wherein the polynucleotide is RNA.
- 4. The polynucleotide of claim 1 wherein the polynucleotide is genomic DNA.
- 5. The polynucleotide of claim 2 wherein said polynucleotide has the deduced amino acid sequence of SEQ ID No. 2.
- 6. The polynucleotide of claim 2 wherein said polynucleotide encodes a polypeptide encoded by the cDNA of ATCC Deposit No. 75902.
- 7. The polynucleotide of claim 1 having the coding sequence as shown in SEQ ID No. 1.
- 8. The polynucleotide of claim 2 having the coding sequence deposited as ATCC Deposit No. 75902.
- 9. A vector containing the DNA of claim 2.
- 10. A host cell genetically engineered with the vector of claim 9.
- 11. A process for producing a polypeptide comprising: expressing from the host cell of claim 10 the polypeptide encoded by said DNA.
- 12. A process for producing cells capable of expressing a polypeptide comprising genetically engineering cells with the vector of claim 9.
- 13. An isolated DNA hybridizable to the DNA of claim 2 and encoding a polypeptide having PGF activity.
- 14. A polypeptide selected from the group consisting of:
(a) a polypeptide having the deduced amino acid sequence of SEQ ID No. 2 and fragments, analogs and derivatives thereof; and (b) a polypeptide encoded by the cDNA of ATCC Deposit No. 75902 and fragments, analogs and derivatives of said polypeptide.
- 15. The polypeptide of claim 14 wherein the polypeptide has the deduced amino acid sequence of SEQ ID No. 2.
- 16. An antibody against the polypeptide of claim 14.
- 17. An antagonist against the polypeptide of claim 14.
- 18. A method for the treatment of a patient having need of PGF comprising: administering to the patient a therapeutically effective amount of the polypeptide of claim 14.
- 19. The method of claim 18 wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide in vivo.
- 20. A method for the treatment of a patient having need to inhibit PGF comprising: administering to the patient a therapeutically effective amount of the antagonist of claim 17.
- 21. The method of claim 20 wherein said antagonist is administered to treat benign prostatic hyperplasia or prostate cancer.
- 22. A process for identifying compounds active as agonists to PGF comprising:
(a) combining a compound to be screened, and a reaction mixture containing cells under conditions where the cells are normally stimulated by PGF, said reaction mixture containing a label incorporated in to the cells as they proliferate; and (b) determining the extent of proliferation of the cells to identify if the compound is an effective agonist.
- 23. The process of claim 22 for identifying compounds active as antagonists to PGF, wherein PGF is added to the combination of step (a).
- 24. A process for diagnosing a disease or a susceptibility to a disease related to a mutation in PGF nucleic acid sequence comprising:
(a) isolating a nucleic acid sequence encoding PGF from a sample derived from a host; and (b) determining a mutation in the PGF nucleic acid sequence.
- 25. A diagnostic process comprising: analyzing for the presence of the polypeptide of claim 14 in a sample derived from a host.
CLAIM TO PRIORITY
[0001] This application is a Divisional of and claims priority under 35 U.S.C. §120 to U.S. application Ser. No. 09/361,741, filed Jul. 28, 1999; this application is also a Divisional of and claims priority under 35 U.S.C. §120 to U.S. application Ser. No. 09/461,418, filed Nov. 18, 1999; said U.S. application Ser. No. 09/361,741 is a Divisional of and claims priority under 35 U.S.C. §120 to U.S. application Ser. No. 08/411,607, filed Apr. 11, 1995 (now U.S. Pat. No. 5,994,102); said U.S. application Ser. No. 09/461,418 is a Continuation of and claims priority under 35 U.S.C. §120 to U.S. application Ser. No. 08/411,607, filed Apr. 11, 1995 (now U.S. Pat. No. 5,994,102); said U.S. application Ser. No. 08/411,607 (now U.S. Pat. No. 5,994,102) claims priority under 35 U.S.C. §120 of PCT/US94/14578 filed Dec. 15, 1994; all of which are hereby incorporated by reference in their entirety.
Divisions (3)
|
Number |
Date |
Country |
Parent |
09361741 |
Jul 1999 |
US |
Child |
10270377 |
Oct 2002 |
US |
Parent |
08411607 |
Apr 1995 |
US |
Child |
09361741 |
Jul 1999 |
US |
Parent |
09461418 |
Dec 1999 |
US |
Child |
10270377 |
Oct 2002 |
US |
Continuations (2)
|
Number |
Date |
Country |
Parent |
08411607 |
Apr 1995 |
US |
Child |
09461418 |
Dec 1999 |
US |
Parent |
PCT/US94/14578 |
Dec 1994 |
US |
Child |
09461418 |
Dec 1999 |
US |